EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia.

Monica M, Becirovic S, Bianchi-Manaila I, Duborija-Kovacevic N, Draganic P, Garouliene K, Hammerman A, Ispan F, Ivanova B, Männik A, Meresz G, Nazaryan L, Oleshchuk O, Savova A, Skoupa J, Stefanovic N, Tesar T, Kawalec P

Open source

DOI
10.3389/fphar.2025.1629465
Published
2025
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2025.1629465,
  title = {EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia.},
  author = {Monica M and Becirovic S and Bianchi-Manaila I and Duborija-Kovacevic N and Draganic P and Garouliene K and Hammerman A and Ispan F and Ivanova B and Männik A and Meresz G and Nazaryan L and Oleshchuk O and Savova A and Skoupa J and Stefanovic N and Tesar T and Kawalec P},
  year = {2025},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2025.1629465},
  url = {https://doi.org/10.3389/fphar.2025.1629465}
}

RIS

TY  - JOUR
TI  - EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia.
AU  - Monica M
AU  - Becirovic S
AU  - Bianchi-Manaila I
AU  - Duborija-Kovacevic N
AU  - Draganic P
AU  - Garouliene K
AU  - Hammerman A
AU  - Ispan F
AU  - Ivanova B
AU  - Männik A
AU  - Meresz G
AU  - Nazaryan L
AU  - Oleshchuk O
AU  - Savova A
AU  - Skoupa J
AU  - Stefanovic N
AU  - Tesar T
AU  - Kawalec P
PY  - 2025
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2025.1629465
UR  - https://doi.org/10.3389/fphar.2025.1629465
ER  - 

APA

M, M., S, B., I, B., N, D., P, D., K, G., A, H., F, I., B, I., A, M., G, M., L, N., O, O., A, S., J, S., N, S., T, T., & P, K. (2025). EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2025.1629465

Source records